Logo image of BOLT

BOLT BIOTHERAPEUTICS INC (BOLT) Stock Fundamental Analysis

NASDAQ:BOLT - Nasdaq - US0977021049 - Common Stock - Currency: USD

0.358  -0.01 (-3.24%)

After market: 0.3512 -0.01 (-1.9%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BOLT. BOLT was compared to 563 industry peers in the Biotechnology industry. BOLT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BOLT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BOLT has reported negative net income.
BOLT had a negative operating cash flow in the past year.
BOLT had negative earnings in each of the past 5 years.
In the past 5 years BOLT always reported negative operating cash flow.
BOLT Yearly Net Income VS EBIT VS OCF VS FCFBOLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

BOLT has a worse Return On Assets (-63.35%) than 62.34% of its industry peers.
The Return On Equity of BOLT (-110.35%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -63.35%
ROE -110.35%
ROIC N/A
ROA(3y)-48.44%
ROA(5y)-61.59%
ROE(3y)-74.37%
ROE(5y)-4101.17%
ROIC(3y)N/A
ROIC(5y)N/A
BOLT Yearly ROA, ROE, ROICBOLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

1.3 Margins

BOLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BOLT Yearly Profit, Operating, Gross MarginsBOLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

BOLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
BOLT has more shares outstanding than it did 1 year ago.
BOLT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BOLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BOLT Yearly Shares OutstandingBOLT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BOLT Yearly Total Debt VS Total AssetsBOLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

BOLT has an Altman-Z score of -7.57. This is a bad value and indicates that BOLT is not financially healthy and even has some risk of bankruptcy.
BOLT has a worse Altman-Z score (-7.57) than 69.09% of its industry peers.
BOLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.57
ROIC/WACCN/A
WACC10.1%
BOLT Yearly LT Debt VS Equity VS FCFBOLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 3.20 indicates that BOLT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.20, BOLT is doing worse than 63.23% of the companies in the same industry.
BOLT has a Quick Ratio of 3.20. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.20, BOLT is not doing good in the industry: 60.39% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 3.2
BOLT Yearly Current Assets VS Current LiabilitesBOLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

BOLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.94%, which is quite good.
Looking at the last year, BOLT shows a decrease in Revenue. The Revenue has decreased by -2.40% in the last year.
BOLT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 103.56% yearly.
EPS 1Y (TTM)16.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.15%
Revenue 1Y (TTM)-2.4%
Revenue growth 3Y82.75%
Revenue growth 5Y103.56%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 15.10% on average over the next years. This is quite good.
Based on estimates for the next years, BOLT will show a very strong growth in Revenue. The Revenue will grow by 24.13% on average per year.
EPS Next Y4.88%
EPS Next 2Y14.4%
EPS Next 3Y20.44%
EPS Next 5Y15.1%
Revenue Next Year-66.49%
Revenue Next 2Y-22.88%
Revenue Next 3Y17.4%
Revenue Next 5Y24.13%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BOLT Yearly Revenue VS EstimatesBOLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
BOLT Yearly EPS VS EstimatesBOLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BOLT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BOLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BOLT Price Earnings VS Forward Price EarningsBOLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BOLT Per share dataBOLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as BOLT's earnings are expected to grow with 20.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.4%
EPS Next 3Y20.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BOLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (5/9/2025, 8:00:01 PM)

After market: 0.3512 -0.01 (-1.9%)

0.358

-0.01 (-3.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08
Earnings (Next)08-11 2025-08-11
Inst Owners48.23%
Inst Owner Change-0.12%
Ins Owners0.65%
Ins Owner Change0%
Market Cap13.73M
Analysts48.89
Price Target1.15 (221.23%)
Short Float %0.86%
Short Ratio2.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.64%
Min EPS beat(2)-11.25%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)10.73%
Min EPS beat(4)-11.25%
Max EPS beat(4)46.17%
EPS beat(8)7
Avg EPS beat(8)10%
EPS beat(12)10
Avg EPS beat(12)9.71%
EPS beat(16)12
Avg EPS beat(16)0.14%
Revenue beat(2)0
Avg Revenue beat(2)-55.71%
Min Revenue beat(2)-100%
Max Revenue beat(2)-11.41%
Revenue beat(4)2
Avg Revenue beat(4)19.84%
Min Revenue beat(4)-100%
Max Revenue beat(4)150.55%
Revenue beat(8)5
Avg Revenue beat(8)19.19%
Revenue beat(12)9
Avg Revenue beat(12)54.28%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-35.71%
EPS NQ rev (1m)-6.62%
EPS NQ rev (3m)11.59%
EPS NY rev (1m)-26.56%
EPS NY rev (3m)-26.56%
Revenue NQ rev (1m)-13.76%
Revenue NQ rev (3m)91.88%
Revenue NY rev (1m)-25.01%
Revenue NY rev (3m)-37.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.78
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.24
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.2
BVpS1.49
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.35%
ROE -110.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.44%
ROA(5y)-61.59%
ROE(3y)-74.37%
ROE(5y)-4101.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.3%
Cap/Sales 0.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.2
Quick Ratio 3.2
Altman-Z -7.57
F-Score4
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)43.39%
Cap/Depr(5y)172.25%
Cap/Sales(3y)12.39%
Cap/Sales(5y)328.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.15%
EPS Next Y4.88%
EPS Next 2Y14.4%
EPS Next 3Y20.44%
EPS Next 5Y15.1%
Revenue 1Y (TTM)-2.4%
Revenue growth 3Y82.75%
Revenue growth 5Y103.56%
Sales Q2Q%-100%
Revenue Next Year-66.49%
Revenue Next 2Y-22.88%
Revenue Next 3Y17.4%
Revenue Next 5Y24.13%
EBIT growth 1Y10.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.85%
OCF growth 3YN/A
OCF growth 5YN/A